AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
AngioDynamics, Inc. (ANGO)
Last angiodynamics, inc. earnings: 4/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.angiodynamics.com/investor-relations
Company Research
Source: Business Wire
Med Tech segment delivered its sixth consecutive quarter of double-digit growthStrong adjusted EBITDAThird consecutive quarter the Company raised full year FY 2026 guidance for net sales and Adjusted EBITDA LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2026, which ended February 28, 2026.Fiscal Year 2026 Third Quarter Highlights Quarter EndedFebruary 28, 2026 Pro Forma* YoY GrowthNet Sales $78.4 million 8.9%Med Tech Net Sales $37.3 million 19.0%Med Device Net Sales $41.1 million 1.1%GAAP gross margin of 52.9%GAAP loss per share of $0.19Adjusted loss per share of $0.07Adjusted EBITDA of $1.8 millionEnded fiscal 2026 third quarter with $37.8 million in cash, in line with expectations*Pro f
Show less
Read more
Impact Snapshot
Event Time:
ANGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANGO alerts
High impacting AngioDynamics, Inc. news events
Weekly update
A roundup of the hottest topics
ANGO
News
- AngioDynamics (ANGO) had its price target lowered by Canaccord Genuity Group Inc. from $18.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- AngioDynamics Growing, But With More Noise Than The Street Likes [Seeking Alpha]Seeking Alpha
- AngioDynamics Inc (ANGO) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amid Financial ... [Yahoo! Finance]Yahoo! Finance
- AngioDynamics Q3 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- AngioDynamics (ANGO) was downgraded by Zacks Research from "strong-buy" to "hold".MarketBeat
ANGO
Earnings
- 4/2/26 - Beat
ANGO
Analyst Actions
- 4/6/26 - Canaccord Genuity
ANGO
Sec Filings
- 4/2/26 - Form 10-Q
- 4/2/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- ANGO's page on the SEC website